Results 91 to 100 of about 3,849 (286)
Analyzing growth and hepatotoxin production in cyanobacteria using flux balance analysis of a metabolic network model [PDF]
, 2013 Full text is available to authenticated members of The University of Auckland only.Global supplies of drinking water are increasingly under threat from toxic cyanobacterial blooms. Although the phenomena have been extensively studied, no factors have yet
Jayakumar, Athira
core
Advanced Science, EarlyView.A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong +13 more
wiley +1 more source
Investigation of Microcystin Processing, Production and Export by Microcystis sp. [PDF]
, 2014 During this study, the effect of different processing methods on the microcystin quota (microcystins per cell) was investigated. Microcystins from two Microcystis strains and one Planktothrix strain were quantified using liquid chromatography-mass ...
Rogers, Shelley
core
Toxins, 2019 Understanding of colony specific properties of cyanobacteria in the natural environment has been challenging because sampling methods disaggregate colonies and there are often delays before they can be isolated and preserved.
Jonathan Puddick +4 more
doaj +1 more source
Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery
Advanced Science, EarlyView.Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae +27 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan +22 more
wiley +1 more source
Advanced Science, EarlyView.A thermo‐responsive rectal delivery platform integrating probiotic‐derived extracellular vesicles within a hyaluronic acid‐based copolymer enables localized and sustained therapy for ulcerative colitis. The formulation effectively suppresses inflammation, promotes macrophage polarization toward a regenerative phenotype, restores epithelial barrier ...
Ayushi Mairal +5 more
wiley +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Advanced Science, EarlyView.GCs reduce Parkin, leading to ACSL4 accumulation and PUFA‐phospholipid‐driven ferroptosis in BMSCs, which impairs osteogenesis and promotes adipogenesis, causing GIOP. Parkin restoration (via OE‐Parkin or Parkin‐LNP@DSS6) ubiquitinates and degrades ACSL4, inhibiting ferroptosis, rescuing bone formation, and rescues GIOP bone loss.
Li‐jiang Han +16 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source